Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Pharvaris BV(PHVS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PHVS
09/15/2026: PHVS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Pharvaris BV is a clinical-stage biotechnology company focused on developing oral bradykinin B2-receptor antagonists to treat hereditary angioedema (HAE). Its primary strength is a specialized pipeline that seeks to replace injectable therapies with a more convenient once-daily oral pill. The main investment opportunity lies in the potential for its lead candidate, deucrictibant, to capture significant market share if it achieves regulatory approval. However, the company faces substantial execution, competitive, and financial risks, as it currently lacks commercial revenue. The stock is best suited for risk-tolerant investors with a high appetite for speculative biotechnology ventures who are closely monitoring clinical trial news and regulatory outcomes.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk, high-reward play on future drug approval that may appeal to those seeking long-term capital appreciation. |
| Momentum investor | Strong fit while signal remains positive | The stock often reacts sharply to clinical and regulatory news cycles, creating significant short-term trading opportunities. |
| Value investor | Weak fit | The company lacks current earnings or traditional value metrics, making it unsuitable for standard value-based investing. |
| Dividend investor | Weak fit | The company does not pay dividends and operates in a cash-burning phase. |
| Low-risk investor | Weak fit | The extreme volatility associated with pre-commercial biotech development poses significant capital risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results can cause massive swings in share price. |
| Valuation risk | High | Valuations are driven by future potential, which is inherently speculative. |
| Competition risk (HAE treatments) | High | Entrenched incumbents may protect their market share aggressively. |
| Business quality | Medium | The firm is specialized but pre-revenue, lacking a commercial track record. |
| Dividend income | Low / none | Investors should not expect income from this equity. |
| Execution risk | Medium / high | Success depends entirely on successful clinical trials and regulatory approval. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -6.51% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.73B USD | Price to earnings Ratio - | 1Y Target Price 58.63 |
Price to earnings Ratio - | 1Y Target Price 58.63 | ||
Volume (30-day avg) 941.0K shares | Beta -2.32 | 52 Weeks Range 20.65 - 43.25 | Updated Date 09/15/2026 |
52 Weeks Range 20.65 - 43.25 | Updated Date 09/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.03 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| HAE Therapeutics | Development of deucrictibant for HAE. | The company currently makes no money; it is betting on the future sale of a breakthrough pill. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2.36B | Price to Sales(TTM) - |
Enterprise Value 2.36B | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.38 | Shares Outstanding 70.20M | Shares Floating 43.70M |
Shares Outstanding 70.20M | Shares Floating 43.70M | ||
Percent Insiders 6.08 | Percent Institutions 93.14 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Pharvaris BV
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2021-02-05 | Co-Founder, CEO & Executive Director Mr. Berndt Axel Edvard Modig CPA, M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 148 | Website https://pharvaris.com |
Full time employees 148 | Website https://pharvaris.com | ||
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.